- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05846789
Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers
A Phase II Trial of Carboplatin +/- Tocilizumab as Initial Therapy for Metastatic Triple Negative and ER-low Breast Cancers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Xin Bryan, RN
- Phone Number: 317-274-5495
- Email: zhongx@iupui.edu
Study Locations
-
-
Indiana
-
Carmel, Indiana, United States, 46032
- Recruiting
- IU Health Joe and Shelly Schwarz Cancer Center
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Sidney and Lois Eskenazi Hospital
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center
-
Contact:
- Xin Bryan, RN
- Phone Number: 317-274-5495
- Email: zhongx@iupui.edu
-
Principal Investigator:
- Kathy Miller, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥ 18 years old at the time of informed consent
- Ability to provide written informed consent and HIPAA authorization
- Locally recurrent (not amenable to local therapy with curative intent) or metastatic breast cancer that is triple negative or ER-low (ER and PR ≤ 9% weak staining)
No prior chemotherapy for metastatic disease
a. Prior (neo)adjuvant therapy must have been completed at least 12 months from diagnosis of unresectable locally recurrent or metastatic disease.
- Measurable disease based on RECIST 1.1 criteria.
Disease amenable to and consent for study-specific biopsy
a. NOTE: If no disease amenable to biopsy is present at the time of second biopsy, subjects may continue participation in the study and further study specific biopsies will not be required.
- ECOG PS 0 or 1
- Patients with treated, asymptomatic CNS disease may participate if the patient is > 4 weeks from completion of CNS therapy (radiation and/or surgery), is clinically stable at the time of study entry, and is receiving a stable or decreasing dose of corticosteroid therapy. Brain MRI or head CT is required at screening for patients with known brain metastases.
Adequate organ function as indicated by:
- Total bilirubin < ULN (except in patients with documented Gilbert's disease, who must have a total bilirubin < 3.0 mg/dL)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5.0 x ULN
- Creatinine clearance of > 50 mL/min using the Cockcroft-Gault formula
- Absolute neutrophil count (ANC) > 1.5 K/mm3
- Platelets > 100 K/ mm3
- Hgb > 9.0 g/dL
Women of childbearing potential must have a negative pregnancy test within 14 days of protocol registration. Women are considered to have childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) unless they meet one of the following criteria:
- Has undergone a hysterectomy or bilateral oophorectomy; or
- Has been naturally amenorrheic for at least 24 consecutive months.
- Women of childbearing potential and men must agree to use effective contraception throughout the study and for 6 months after the last study treatment.
Note: Acceptable methods of birth control include abstinence, partner with previous vasectomy, placement of an intrauterine device (IUD), condom with spermicidal foam/gel/film/cream/suppository, diaphragm or cervical vault cap, or hormonal birth control (pills or injections).
Exclusion Criteria:
- Prior treatment with or known contraindication to treatment with tocilizumab or other IL-6/IL-6R targeted agent
- Patients who are PD-L1 positive (CPS ≥ 10), unless they have a clear contraindication to pembrolizumab therapy.
- Active infection requiring parenteral antibiotics
- Concurrent use of methotrexate or systemic corticosteroids
- Active or symptomatic CNS disease
- Patients with HER2+ disease HER2 will be considered positive if scored 3+ by immunohistochemistry (IHC) or 2+ by IHC associated with a fluorescence in situ hybridization (FISH) ratio of > 2.0 or > 6 total HER2 gene copies per cell.
- Patients with active malignancy other than breast cancer. Patients with prior malignancies without recurrence after standard treatment will not be excluded
- Radiation therapy within 2 weeks of registration
- Hormone therapy within 2 weeks of registration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Black Monotherapy
|
Carboplatin will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.
|
Experimental: Black Combination treatment
|
Carboplatin will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.
Tocilizimab 8 mg/ actual body weight in kg IV q4 weeks
|
Active Comparator: Non-Black Monotherapy
|
Carboplatin will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.
|
Experimental: Non-Black Combination treatment
|
Carboplatin will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.
Tocilizimab 8 mg/ actual body weight in kg IV q4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate
Time Frame: through study completion (i.e. up to 2 years)
|
through study completion (i.e. up to 2 years)
|
|
Efficacy of tocilizumab in Black and non-Black patients
Time Frame: through study completion (i.e. up to 2 years)
|
efficacy defined as using the difference in difference approach across race based cohorts
|
through study completion (i.e. up to 2 years)
|
Progression-free survival
Time Frame: through study completion (i.e. up to 2 years)
|
through study completion (i.e. up to 2 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of carboplatin monotherapy compared to carboplatin combined with tocilizumab using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 5.0
Time Frame: through study completion (i.e. up to 2 years)
|
through study completion (i.e. up to 2 years)
|
|
Evaluate the differences in inflammatory pathways between Black and non-Black patients
Time Frame: Baseline
|
Tumor PZP, IL-6, and phosphoSTAT3
|
Baseline
|
Evaluate the impact of Duffy genotype on efficacy in Black patients
Time Frame: Baseline
|
Tumor PZP, IL-6, and phosphoSTAT3 between Duffy-null, Duffy-heterozygous, and Duffy-wild type
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kathy Miller, MD, Indiana University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTO-IUSCCC-0817
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
Clinical Trials on Carboplatin
-
Eisai Inc.CompletedCancerUnited States, Austria, India
-
Samyang Biopharmaceuticals CorporationCompleted
-
NHS Greater Glasgow and ClydeCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited Kingdom, Australia, New Zealand
-
Duke UniversityCompletedBrain and Central Nervous System TumorsUnited States, Canada
-
National Cancer Institute (NCI)CompletedBreast Cancer | Ovarian CancerUnited States
-
National Cancer Institute (NCI)Children's Oncology GroupCompletedBrain and Central Nervous System TumorsUnited States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
-
All India Institute of Medical Sciences, New DelhiCouncil of Scientific and Industrial Research, IndiaUnknownIntraocular RetinoblastomaIndia
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Eli Lilly and CompanyCompletedLung NeoplasmsUnited States
-
AkesoRecruitingAdvanced Squamous Non Small Cell Lung CancerChina